Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probioflor
- Development stage
- Unknown
- Lead developer
- Vector-BiAlgam
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probioflor is a line of probiotic products developed and manufactured by the Russian biotechnology company AO Vector-BiAlgam. The product line includes specific formulations such as Probioflor-L, which contains *Lactobacillus plantarum* and *Lactobacillus fermentum*, and Probioflor-B, which contains *Bifidobacterium bifidum*. These probiotics are designed to restore and maintain the balance of the intestinal microflora by introducing high concentrations of live, antagonistic bacteria. They function by competing with pathogenic and opportunistic microorganisms for nutrients and adhesion sites, producing antimicrobial metabolites like lactic acid and bacteriocins, and modulating the host's mucosal immune system. Probioflor is primarily indicated for the prevention and treatment of dysbiosis, recovery after antibiotic therapy, and the management of various gastrointestinal disturbances. It is registered in Russia as a biologically active additive (BAA).
- Brand names
- ProbioflorProbioflor-LProbioflor-BProbioflor-Complex
- Other names
- Probioflor-AO Vector-BiAlgam-probiotic
Beyond the preview
Go deeper on Probioflor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probioflor.